secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001711279-23-000074
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech reports first VYJUVEK revenue of $8.6M; net income $80.7M in Q3 2023
--------------------------------------------------------------------------------

- VYJUVEK net product revenue $8.6M in Q3 2023; 284 Patient Start Forms from 136 prescribers; patient compliance 96%.
- Net income $80.7M ($2.79 diluted EPS) vs net loss ($29.9M) year-ago; includes $100M gain on PRV sale.
- Cash, equivalents and investments $598.6M; R&D expense $10.6M; SG&A $23.7M.
- Pipeline: Cohort 1 complete in Phase 1 KB407 (CF); first patient dosed in Phase 1 KB707 (solid tumors); IND cleared for KB408 (AATD).
- B-VEC filed for EU marketing authorization; Japan extension study dosed 5 patients; PRV sold for $100M; ASTRA facility operational.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000074/0001711279-23-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000074/krys-20231106.htm
  HTML page:      https://secwatch.observer/filing/0001711279-23-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer